Genetic aspects of Parkinson's disease

Movement Disorders

Volumn 13, Issue 2, 1998, Pages 203-211

  Bandmann, Oliver ^a   Marsden, C David ^a   Wood, Nicholas W ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MITOCHONDRIAL DNA; SUPEROXIDE DISMUTASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; CONTROLLED STUDY; FAMILIAL DISEASE; FAMILY HISTORY; FEMALE; GENE FUNCTION; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MOLECULAR GENETICS; MOUSE; NONHUMAN; PARKINSON DISEASE; PEDIGREE ANALYSIS; PRIORITY JOURNAL; REVIEW; TWINS;

ANIMALS; GENETIC MARKERS; HUMANS; MICE; MICE, NEUROLOGIC MUTANTS; MODELS, GENETIC; PARKINSON DISEASE; RECEPTORS, DOPAMINE; TWIN STUDIES;

EID: 0031905933     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.870130203     Document Type: Review

References (100)

1. Nasir J, Goldberg Y, Hayden M. Huntington disease: new insights into the relationship between CAG expansion and disease. Hum Mol Genet 1996:5:1431-1435.
2. Gowers W. A manual of diseases of the nervous system. London: J & A Churchill, 1888:589f.
3. Kückens H. Über Heredofamiliarität bei Paralysis agitans. Klin Wochenschr 1925;4:2289-2291.
4. Mjönes H. Paralysis agitans. A clinical genetic study. Acta Neurol Scand 1949;25(suppl 54):1-195.
5. Duvosin R. The genetics of Parkinson's disease. Adv Neurol 1993;60:306-315.
6. Payami H, Larsen K, Bernard S, Nutt J. Increased risk of Parkinson's disease in parents and siblings of patients. Ann Neurol 1994;36:659-661.
7. Seidler A, Hellenbrand W, Robra B-P, et al. Possible environmental, occupational and other etiologic factors for Parkinson's disease: a case control study in Germany. Neurology 1996;46:1275-1284.
8. De Michele G, Filla A, Volpe G, et al. Environmental and genetic risk factors in Parkinson's disease: a case-control study in southern Italy. Mov Disord 1996;11:17-23.
9. Semchuk K, Love E, Lee R. Parkinson's disease: a test of the multifactorial etiologic hypothesis. Neurology 1993;43:1173-1180.
10. Marder K, Tang M-X, Mejia H, et al. Risk of Parkinson's disease among first degree relatives: a community based study. Neurology 1996;47:155-160.
11. Fleming L, Mann J, Bean J, Briggle T, Sanchez-Ramos J. Parkinson's disease and brain levels of organochlorine pesticides. Ann Neurol 1994;36:100-103.
12. Martyn C, Osmond C. Parkinson's disease and the environment in early life. J Neurol Sci 1995;132:201-206.
13. Quinn N, Critchley P, Marsden CD. Young onset Parkinson's disease. Mov Disord 1987;2:73-91.
14. Takahashi H, Ohama E, Suzuki S, et al. Familial juvenile parkinsonism: clinical and pathologic study in a family. Neurology 1994;44:437-441.
15. Vogel F, Motulski A. Population genetics. In: Vogel F, Motulski A, eds. Human genetics: problems and approaches. Berlin: Springer, 1986:205-218.
16. Marsden CD. Parkinson's disease in twins. J Neurol Neurosurg Psychiatry 1987;50:105-106.
17. Martilla R, Kaprio J, Kostenvuo M, Rinne U. Parkinson's disease in a nationwide twin cohort. Neurology 1988;38:1217-1219.
18. Ward C, Duvoisin R, Ince S, Nutt J, Eldridge R, Calne D. Parkinson's disease in 65 pairs of twins and in a set of quadruplets. Neurology 1983;33:815-824.
19. Johnson W, Hodge S, Duvoisin R. Twin studies and the genetics of Parkinson's disease - a reappraisal. Mov Disord 1990;5:187-194.
20. Vieregge P, Schiffke K, Friedrich H, Müller B, Ludin H. Parkinson's disease in twins. Neurology 1992;42:1453-1461.
21. Gibb W, Lees A. The relevance of the Lewy body in the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988;51:745-752.
22. Burn D, Mark M, Playford E, et al. Parkinson's disease in twins studied with 18F-dopa and positron emission tomography. Neurology 1992;42:1894-1900.
23. Holthoff V, Vieregge P, Kessler J, et al. Discordant twins with Parkinson's disease: positron emission tomography and early signs of impaired cognitive circuits. Ann Neurol 1994;36:176-182.
24. Hughes A, Daniel S, Kilford L, Lees A. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinicopathological study. J Neurol Neurosurg Psychiatry 1992;55:181-184.
25. Bell J, Clark A. A pedigree of paralysis agitans. Annals of Eugenics 1926;1:455-462.
26. Golbe L, Lazzarini A, Schwarz K, Mark M, Dickson D, Duvoisin R. Autosomal dominant parkinsonism with benign course and typical Lewy-body pathology. Neurology 1993;43:2222-2227.
27. Golbe L, Di Iorio G, Sanges G, et al. Clinical genetic analysis of Parkinson's disease in the Contursi kindred. Ann Neurol 1996;40:767-775.
28. Polymeropoulos M, Higgins J, Golbe L, et al. Mapping of a gene for Parkinson's disease to chromosome 4q21-23. Science 1996;274:1197-1199.
29. Gasser T. Muller-Myhsok B, Wszolek ZK, et al. Genetic heterogeneity in familial parkinsonism: no linkage to the PD-1 locus on chromosome 4q in 11 of 13 families. Science 1997;277:388-389.
30. Levy-Lahad E, Bird T. Genetic factors in Alzheimer's disease: a review of recent advances. Ann Neurol 1996;40:829-840.
31. Siddique T, Deng H-X. Genetics of amyotrophic lateral sclerosis. Hum Mol Genet 1996;5:1465-1470.
32. Wszolek Z, Pfeiffer B, Fulgham J, et al. Western Nebraska family (family D) with autosomal dominant parkinsonism. Neurology 1995;45:502-505.
33. Waters C, Miller C. Autosomal dominant Lewy body parkinsonism in a four-generation family. Ann Neurol 1994;35:59-64.
34. Degl'Innocenti F, Maurello M, Marini P. A parkinsonian kindred. Ital J Neurol Sci 1989;10:307-310.
35. Markopoulou K, Wszolek ZK, Pfeiffer RF. A Greek-American kindred with autosomal dominant, levodopa-responsive parkinsonism and anticipation. Ann Neurol 1995;38:373-378.
36. Piccini P, Morrish PK, Turjanski N, et al. Dopaminergic function in familial Parkinson's disease: a clinical and 18F-dopa study. Ann Neurol 1997;41:222-229.
37. Sawle GV, Wroe SJ, Lees AJ, et al. The identification of presymptomatic parkinsonism: clinical and 18F-dopa positron emission tomography studies in an Irish kindred. Ann Neurol 1992;32:609-617.
38. Willems P. Dynamic mutations hit double figures. Nat Genet 1994;8:221-228.
39. Payami H, Bernard S, Larsen K, Kaye J, Nutt J. Genetic anticipation in Parkinson's disease. Neurology 1995;45:135-138.
40. Maraganore D, Schaid D, Rocca W, Harding AE. Anticipation in familial Parkinson's disease: a reanalysis of 13 United Kingdom kindreds. Neurology 1996;47:1512-1517.
41. Wszolek ZK, Cordes M, Calne DB, Münter MD, Cordes I, Pfeifer RF. Hereditärer Morbus Parkinson: Bericht über drei Familien mit autosomal-dominantem Erbgang. Nervenarzt 1993;64:331-335.
42. Carrero-Valenzuela R, Lindblad K, Payami H, et al. No evidence for association of familial Parkinson's disease with CAG repeat expansion. Neurology 1995;45:1760-1763.
43. Gasser T, Wszolek Z, Trofatter J, et al. Genetic linkage studies in autosomal dominant parkinsonism: evaluation of seven candidate genes. Ann Neurol 1994;36:387-396.
44. Supala A, Wszolek Z, Trofatter J, et al. Genetic linkage studies in autosomal dominant parkinsonism: evaluation of candidate genes. Mov Disord 1994;9:32.
45. Plante-Bordeneuve P, Davis M, Maraganore D, Marsden CD, Harding AE. Debrisoquine hydroxylase gene polymorphism in familial Parkinson's disease. J Neurol Neurosurg Psychiatry 1994;57:911-913.
46. Plante-Bordeneuve V, Davis M, Maraganore D, Marsden C, Harding A. Tyrosine hydroxylase gene polymorphism in familial and sporadic Parkinson's disease. Mov Disord 1994;9:337-339.
47. Rosen D, Siddique T, Patterson D, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993;362:59-62.
48. Burrow J, Blumbergs P. Substantia nigra degeneration in motor neuron disease: a quantitative study. Aust NZ J Med 1992;22:469-472.
49. Takahashi H, Snow B, Bhatt M, Peppard R, Eisen A, Calne D. Evidence for a dopaminergic deficit in sporadic amyotrophic lateral sclerosis on positron emission scanning. Lancet 1993;342:1016-1018.
50. Majoor-Krakauer D, Ottman R, Johnson W, Rowland L. Familial aggregation of amyotrophic lateral sclerosis, dementia, and Parkinson's disease: evidence of shared genetic susceptibility. Neurology 1994;44:1872-1877.
51. Przedborski S, Kostic V, Jackson-Lewis V, et al. Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity. J Neurosci 1992;12:1658-1667.
52. Bandmann O, Davis M, Marsden CD, Harding AE. Sequence of the superoxide dismutase 1 (SOD1) gene in familial Parkinson's disease. J Neurol Neurosurg Psychiatry 1995;59:90-91.
53. Parboosingh J, Rousseau M, Rogan F, et al. Absence of mutations in superoxide dismutase and catalase genes in patients with Parkinson's disease. Arch Neurol 1995;52:1160-1163.
54. Tuite P, Rogaeva E, St George-Hyslop PH, et al. Dopa-responsive parkinsonism phenotype of Machado-Joseph disease: confirmation of 14q CAG expansion. Ann Neurol 1995;38:684-687.
55. Dexter D, Sian J, Rose S, et al. Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease. Ann Neurol 1994;35:38-44.
56. Barbeau A, Cloutier T, Roy M, Plasse L, Paris S, Poirier J. Ecogenetics of Parkinson's disease: 4-hydroxylation of debrisoquine. Lancet 1985;1213-1215.
57. Benitez J, Ladero J, Jimenez F, et al. Oxidative polymorphism of debrisoquine in Parkinson's disease. J Neurol Neurosurg Psychiatry 1990;53:289-292.
58. Kallio J, Marttila R, Rinne U, Sonninen V, Syvälahti E. Debrisoquine oxidation in Parkinson's disease. Acta Neurol Scand 1991;83:194-197.
59. Steiger M, Lledo P, Quinn N, Marsden D, Turner P, Jenner P. Debrisoquine hydroxylation in Parkinson's disease. Acta Neurol Scand 1992;86:159-164.
60. Armstrong M, Daly A, Cholerton S, Bateman D, Idle J. Mutant debrisoquine hydroxylation genes in Parkinson's disease. Lancet 1992;339:1017-1018.
61. Smith C, Gough A, Leigh P, et al. Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease. Lancet 1992;339:1375-1377.
62. Kurth M, Kurth J. Variant cytochrome P450 CYP2D6 allelic frequencies in Parkinson's disease. Am J Med Genet 1993;48:166-168.
63. Agundez J, Jimenez-Jimenez F, Luengo A, et al. Association between the oxidative polymorphism and early onset of Parkinson's disease. Clin Pharmacol Ther 1995;57:291-298.
64. Gasser T, Müller-Myhsok B, Supala A, et al. The CYP2D6B allele is not overrepresented in a population of German patients with idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1996;61:518-520.
65. Diederich N, Hilger C, Goetz C, Vieregge P, Metz H. Genetic variability of the CYP2D6 gene is not a risk factor for sporadic Parkinson's disease. Ann Neurol 1996;40:463-465.
66. Sandy M, Armstrong M, Tanner C, et al. CYP2D6 allelic frequencies in young-onset Parkinson's disease. Neurology 1996;47:225-230.
67. Ibarreta D, Gomez-Isla T, Portera-Sanchez A, Parrilla R, Ayuso M. Apolipoprotein E genotype in Spanish patients of Alzheimer's or Parkinson's disease. J Neurol Sci 1995;134:146-149.
68. Koller W, Glatt S, Hubble J, et al. Apolipoprotein E genotypes in Parkinson's disease with and without dementia. Ann Neurol 1995;37:242-245.
69. Whitehead A. Bertrandy S, Finnan F, Butler A, Smith G, Ben-Shlomo Y. Frequency of the apolipoprotein E e4 allele in a case-control study of early onset Parkinson's disease. J Neurol Neurosurg Psychiatry 1996;61:347-351.
70. Riederer P, Konradi C, Hebenstreit G, Youdim M. Neurochemical perspectives to the function of monoamine oxidase. Acta Neurol Scand 1989:126:41-45.
71. Langston J, Irwin I, Tetrud J, Langston E, Forno E. Pargyline prevents MPTP induced parkinsonism in primates. Science 1984;225:1480-1482.
72. Kurth J, Kurth M, Poduslo S, Schwankhaus J. Association of a monoamine oxidase B allele with Parkinson's disease. Ann Neurol 1993;33:368-372.
73. Ho S, Kapadi A, Ramsden D. Williams A. An allelic association study of monoamine oxidase B in Parkinson's disease. Ann Neurol 1995;37:403-405.
74. Hotamisligil G, Girmen A, Fink J, et al. Hereditary variations in monoamine oxidase as a risk factor for Parkinson's disease. Mov Disord 1994;9:305-310.
75. Higuchi S, Muramatsu T, Arai H, Hayashida M, Sasaki H, Trojanowski J. Polymorphisms of dopamine receptor and transporter genes and Parkinson's disease. J Neural Transm 1995;10:107-113.
76. Baker H, Joh T, Reis D. Genetic control of number of midbrain dopaminergic neurons in inbred strains of mice: relationship to size and neuronal density of the striatum. Proc Natl Acad Sci USA 1980;77:4369-4373.
77. Caspar P, Ben Jelloun N, Febvret A. Sparing of the dopaminergic neurons containing calbindin-D28k and of the dopaminergic mesocortical projections in weaver mutant mouse. Neuroscience 1994;61:293-305.
78. Gupta M, Feiten D, Ghetti B. Selective loss of monoaminergic neurons in weaver mutant mice - an immunocytochemical study. Brain Res 1987;402:379-382.
79. Schmidt M, Sawyer B, Perry K, Fuller R, Foreman M, Ghetti B. Dopamine deficiency in the weaver mutant mouse. J Neurosci 1982;2:376-380.
80. Verney C, Febvret-Muzerelie A, Caspar P. Early postnatal changes of the dopaminergic mesencephalic neurons in the weaver mouse. Brain Res Dev Brain Res 1995;89:115-119.
81. Paul N, Cox D, Bhat D, Faham M, Myers R, Peterson A. A potassium channel mutation in weaver mice implicates membrane excitability in granule cell differentiation. Nat Genet 1995;11:126-129.
82. Bandmann O, Davis M, Marsden CD, Wood NW. The human homologue of the weaver mouse gene in familial and sporadic Parkinson's disease. Neuroscience 1996;72:877-879.
83. Mochizuki H, Goto K, Mori H, Mizuno Y. Histochemical detection of apoptosis in Parkinson's disease. J Neurol Sci 1996;137:120-123.
84. Hochman A, Offen D, Sternin H, Korsmeyer S, Ziv I, Melamed E. Neurons from bcl-2-deficient mice are more susceptible to dopamine-induced oxidative stress. Mov Disord 1996;11:592-593.
85. Trimmer P, Smith T, Jung A, Bennett J. Dopamine neurons from transgenic mice with a knockout of the p53 gene resist MPTP neurotoxicity. Neurodegeneration 1996;5:233-239.
86. Bennecke R, Struemper P, Weiss H. Electron transfer complexes I and IV of platelets are abnormal in Parkinson's disease but normal in Parkinson-plus syndromes. Brain 1993;116:1451-1463.
87. Haas R, Nasirian F, Nakano K, et al. Low platelet mitochondrial complex I and complex II/III activity in early untreated Parkinson's disease. Ann Neurol 1995;37:714-722.
88. Schapira A, Cooper J, Dexter D, Jenner P, Clark J, Marsden CD. Mitochondrial complex I deficiency in Parkinson's disease [Letter]. Lancet 1989;I:1269.
89. Swerdlow R, Parks J, Miller S, et al. Origin and functional consequences of the complex I defect in Parkinson's disease. Ann Neurol 1996;40:663-671.
90. Lestienne P, Nelson I, Riederer P, Jellinger K, Reichmann H. Normal mitochondrial genome in brain from patients with Parkinson's disease and complex I defects. J Neurochem 1990;55:1810-1812.
91. Mann VM, Cooper JM, Schapira AHV. Quantitation of a mitochondrial DNA deletion in Parkinson's disease. FEBS Lett 1992;299:218-222.
92. Sandy MS, Langston JM, Smith MT, Di Monte DA. PCR analysis of platelet mtDNA: lack of specific changes in Parkinson's disease. Mov Disord 1993;8:74-82.
93. Kösel S, Lücking CB, Egensberger R, Mehraein P, Graeber MB. Mitochondrial NADH dehydrogenase and CYP2D6 genotypes in Lewy-body parkinsonism. J Neurosci Res 1996;44:174-183.
94. Shoffner J, Brown M, Torroni A, et al. Mitochondrial DNA variants observed in Alzheimer disease and Parkinson disease patients. Genomics 1993;17:171-184.
95. Schapira A, Holt I, Sweeney M, Harding AE, Jenner P, Marsden CD. Mitochondrial DNA analysis in Parkinson's disease. Mov Disord 1990;5:294-297.
96. Bandmann O, Sweeney M, Daniel S, Marsden CD, Wood NW. Mitochondrial DNA polymorphisms in pathologically proven Parkinson's disease. J Neurol 1997;244:262-265.
97. Maraganore D, Harding AE, Marsden CD. A clinical and genetic study of familial Parkinson's disease. Mov Disord 1991;6:205-211.
98. Zweig R, Singh A, Cardillo J, Langston J. The familial occurrence of Parkinson's disease. Arch Neurol 1992;49:1205-1207.
99. Wooten G, Currie L, Bennett J, Harrison M, Trugman J, Parker W. Maternal inheritance of Parkinson's disease. Ann Neurol 1997;41:265-268.
100. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 1997;276:2045-2047.